Recent advances on antimony(III/V) compounds with potential activity against tumor cells

Area of Science:

• Medicinal Chemistry
• Inorganic Chemistry
• Cancer Research

Background:

• Antimony compounds have a long history in treating parasitic infections like leishmaniasis.
• Current antimony drugs face challenges including toxicity and parasite resistance.
• Limited research exists on the antitumor potential of antimony compounds.

Purpose of the Study:

• To review the anti-proliferative activity of antimony compounds against cancer cells.
• To elucidate the role of ligand type in the efficacy of antimony complexes.
• To present novel quantitative structure-activity relationship (QSAR) modeling studies for antimony compounds.

Main Methods:

• Literature review of antimony compounds with anti-proliferative activity.
• Analysis of antimony(III/V) complexes with diverse ligands (thiones, thiosemicarbazones, dithiocarbamates, etc.).
• Development and reporting of quantitative structure-activity relationship (QSAR) models.

Main Results:

• Antimony(III/V) complexes with various ligands demonstrate selective anti-proliferative effects on diverse cancer cell lines.
• The type of ligand significantly influences the biological activity of the antimony complexes.
• QSAR models were developed, providing insights into structure-activity relationships.

Conclusions:

• Antimony complexes represent a promising class of compounds for cancer therapy.
• Ligand design is crucial for optimizing the anti-cancer efficacy and selectivity of antimony drugs.
• Further research into antimony compounds, guided by QSAR, could lead to novel anti-cancer therapeutics.